CRPC w/ Bone Metastases

Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases. July 21, 2020

Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study. July 20, 2020

Bone, a Secondary Growth Site of Breast and Prostate Carcinomas: Role of Osteocytes. July 14, 2020

Incidence, prevalence, and outcomes of systemic malignancy with bone metastases. July 13, 2020

Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. July 12, 2020

Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis. July 12, 2020

An agent-based model of prostate Cancer bone metastasis progression and response to Radium223. July 12, 2020

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. March 16, 2020

The Relationship Between Total Lesion Activity on 18F Choline Positron Emission Tomography-Computed Tomography and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Bone Metastases Treated with 223Radium. March 11, 2020

Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. March 9, 2020

Feasibility Study and Preliminary Results of Prognostic Value of Bone SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma to Abiraterone. March 2, 2020

Overall survival and second primary malignancies in men with metastatic prostate cancer. February 25, 2020

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. July 23, 2019

Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel. May 9, 2019

Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States. May 1, 2019

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. January 11, 2019

Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. January 4, 2019

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. January 3, 2019

Reversibility of castration resistance status after Radium-223 dichloride treatment: Clinical evidence and Review of the literature. December 20, 2018

Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging. December 3, 2018

Page 1 of 11